vimarsana.com
  1. Home
  2. Live Updates
  3. Immunogenicity Data Expected - Breaking News

Immunogenicity Data Expected News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic Topline Safety, Tolerability and…

Valent pneumococcal conjugate vaccineImmunogenicity data expectedSecond halfProvide coverageInvasive pneumococcal disease circulatingReaking news

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.